Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment

Morsica, Giulia; Bona, Anna De; Uberti-Foppa, Caterina; Sitia, Giovanni; Finazzi, Renato; Lazzarin, Adriano

doi:10.1097/00002030-200007280-00023

Cited by 39 publications

(21 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This figure is 2-to 3-fold higher than those obtained in HIV-infected nonhemophiliac patients given interferon monotherapy 14,15 and similar to those reported among HIV-HCV-coinfected drug users given interferon and ribavirin combination therapy for 6 to 12 months. [23][24][25][26] As in immunocompetent patients, there was a tendency towards a higher sustained response rate among patients with genotype 2 or 3 (80%) as compared with those with genotype 1 or 4 (27%). Because the present study was designed before data from international trials on combination therapy became available, 18,19 all primary responders at 6 months were intended to complete a 12-month course of treatment irrespective of their HCV genotype.…”

Section: Discussionmentioning

confidence: 99%

“…This finding is in agreement with those reported in similarly treated HIV-infected drug users. [23][24][25][26]28 Mean absolute numbers of CD4 ϩ cells did not change significantly during or after treatment, although a transient decrease was observed in 10 patients, which was counterbalanced by a proportional increase in the remainder. Similarly, no significant change in the proportion of CD4 cells over the total lymphocyte count during the treatment or follow-up was observed.…”

Section: Discussionmentioning

confidence: 99%

“…At 6 months, patients who still had detectable HCV RNA (HCV RNA Ͼ50 IU/mL) were considered nonresponders and had their treatment discontinued, whereas the remaining patients (including those infected with HCV genotypes 2 or 3) continued therapy for a total of 12 months. Patients were monitored monthly during treatment for liver function tests and blood cell counts and at weeks 4,8,12,24,48, and 72 weeks for HCV-RNA and HIV-RNA levels and CD4 cell count. Sustained response to treatment was defined as undetectable HCV RNA (Ͻ50 IU/mL) by second generation reverse transcription polymerase chain reaction (RT-PCR) assay 6 months after the end of treatment.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

Sauleda

2001

Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

Sauleda

2001

Hepatology

View full text Add to dashboard Cite

“…Previous data have suggested that ribavirin-related hemolysis and IFN-induced suppression of hematopoiesis may be worse in HIV-coinfected persons [61,62]. In addition, the drug-drug interaction between ribavirin and didanosine, which leads to increased activity of this NRTI and increased mitochondrial toxicity, has led to great concern about the use of ribavirin among patients taking zidovudine or didanosine [63][64][65][66]. Although it is clear that acceptable rates of sustained virological response to anti-HCV therapy may be achieved in HIV-coinfected patients, these data suggest that the risk of potential adverse events, particularly among patients undergoing HAART who are receiving ribavirin therapy, requires close monitoring by experienced physicians.…”

Section: Treatment Of Hcv Infection Among Drug Users and Minority Popmentioning

confidence: 99%

Coinfection with HIV and Hepatitis C Virus in Injection Drug Users and Minority Populations

Strader

2005

Clinical Infectious Diseases

View full text Add to dashboard Cite

Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is common. In the United States, it has been estimated that 25% of persons infected with HIV are also infected with HCV. The prevalence of coinfection with HIV and HCV is highest among those infected via percutaneous routes. In fact, in urban areas in the United States, 50%-90% of persons infected with HIV via injection drug use are coinfected with HCV. In addition, limited data from drug treatment centers in these urban areas suggest that the prevalence of coinfection with HIV and HCV may be highest among African Americans and Hispanics. Little information is available with regard to the epidemiology of coinfection with HIV and HCV among injection drug users (IDUs) or minority populations. Likewise, although there is a growing body of data on the potential complexities of treating HCV among IDUs and the poor response to current anti-HCV treatment among African Americans, few data address the therapy of coinfection with HIV and HCV among IDUs and minority populations.

show abstract

“…Preliminary studies have reported no evidence of a reduced anti-HIV activity of AZT or d4T when RBV is coadministered. 30,31 However, no data exist on a possible reduced anti-HCV activity of RBV in the presence of AZT or d4T.…”

Section: Pérez-olmeda Et Al 1086 Table 3 Negative Serum Hcv-rna Accmentioning

confidence: 99%

Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α-2b Plus Ribavirin

Pérez‐Olmeda

Soriano

Asensi

et al. 2003

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

One hundred six HIV-infected patients with chronic hepatitis C virus (HCV) infection were randomized to receive ribavirin (RBV) 400 mg bid plus interferon a-2b (IFN-a) at two different doses, 3 mU tiw (control arm) or 5 mU daily for the first 6 weeks, followed by 3 mU tiw until completing 6 months of therapy (induction arm). All patients had CD4 counts above 350 cells/ml and 89% were taking antiretroviral therapy. Adverse effects leading to treatment discontinuation occurred in 12.3% of patients, a rate quite similar to that seen in HCV-monoinfected patients. Negative serum HCV-RNA values (,60 IU/ml) were recorded in 24.7% and 35.5% of patients at 3 and 6 months of therapy. However, in the intent-to-treat analysis, sustained response was reached by only 16% of patients (22.4% in the on-treatment analysis). No differences between treatment arms were noticed. Patients with HCV genotypes 2 or 3 had a 7-fold higher response rate than those with HCV genotypes 1 or 4. Therefore, early, end-of-treatment, and sustained response rates are lower in HIV/HCV-coinfected patients treated with RBV/IFN-a combination therapy. Since HCV-related liver disease is currently one of the leading causes of morbidity and mortality among HIV-infected patients, new treatment options are urgently needed for coinfected individuals.

show abstract

Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment

Cited by 39 publications

References 13 publications

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

Coinfection with HIV and Hepatitis C Virus in Injection Drug Users and Minority Populations

Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α-2b Plus Ribavirin

Contact Info

Product

Resources

About